Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Therapeutic cancer vaccines: past, present, and future.

Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY.

Adv Cancer Res. 2013;119:421-75. doi: 10.1016/B978-0-12-407190-2.00007-1. Review.

2.

DNA vaccines for cancer.

Shaw DR, Strong TV.

Front Biosci. 2006 Jan 1;11:1189-98. Review.

PMID:
16146806
3.

DNA vaccine for cancer immunotherapy.

Yang B, Jeang J, Yang A, Wu TC, Hung CF.

Hum Vaccin Immunother. 2014;10(11):3153-64. doi: 10.4161/21645515.2014.980686. Review.

4.

Cancer vaccines.

Chekhun VF.

Exp Oncol. 2008 Jun;30(2):90. No abstract available.

PMID:
18680872
5.

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.

Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM.

Immunol Rev. 2008 Apr;222:316-27. doi: 10.1111/j.1600-065X.2008.00605.x. Review.

PMID:
18364011
6.

Advances in Therapeutic Cancer Vaccines.

Wong KK, Li WA, Mooney DJ, Dranoff G.

Adv Immunol. 2016;130:191-249. doi: 10.1016/bs.ai.2015.12.001. Review.

PMID:
26923002
7.

Recent developments in therapeutic cancer vaccines.

Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T.

Nat Clin Pract Oncol. 2005 Feb;2(2):108-13. Review.

PMID:
16264883
8.

Specific immunotherapy of cancer in elderly patients.

Matzku S, Zöller M.

Drugs Aging. 2001;18(9):639-64. Review.

PMID:
11599633
9.

Dendritic cell-based vaccine research against cancer.

Mody N, Dubey S, Sharma R, Agrawal U, Vyas SP.

Expert Rev Clin Immunol. 2015 Feb;11(2):213-32. doi: 10.1586/1744666X.2015.987663. Review.

PMID:
25467734
10.

Rethinking therapeutic cancer vaccines.

[No authors listed]

Nat Rev Drug Discov. 2009 Sep;8(9):685-6. doi: 10.1038/nrd2994. No abstract available.

PMID:
19721436
11.

Cancer immunotherapy: sipuleucel-T and beyond.

Hammerstrom AE, Cauley DH, Atkinson BJ, Sharma P.

Pharmacotherapy. 2011 Aug;31(8):813-28. doi: 10.1592/phco.31.8.813. Review.

12.

Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.

Schijns V, Tartour E, Michalek J, Stathopoulos A, Dobrovolskienė NT, Strioga MM.

Cytotherapy. 2014 Apr;16(4):427-39. doi: 10.1016/j.jcyt.2013.09.008. Review.

PMID:
24280238
13.

Personalized dendritic cell-based tumor immunotherapy.

Janikashvili N, Larmonier N, Katsanis E.

Immunotherapy. 2010 Jan;2(1):57-68. Review.

14.

Current perspectives on immunotherapy.

Weber JS.

Semin Oncol. 2014 Oct;41 Suppl 5:S14-29. doi: 10.1053/j.seminoncol.2014.09.003. Review.

15.

IL-13 receptor-directed cancer vaccines and immunotherapy.

Nakashima H, Husain SR, Puri RK.

Immunotherapy. 2012 Apr;4(4):443-51. doi: 10.2217/imt.12.28. Review.

PMID:
22512637
16.

Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.

Bodey B, Bodey B Jr, Siegel SE, Kaiser HE.

Anticancer Res. 2000 Jul-Aug;20(4):2665-76. Review.

PMID:
10953341
17.

DNA vaccines for cancer.

Boyd D, Hung CF, Wu TC.

IDrugs. 2003 Dec;6(12):1155-64. Review.

PMID:
14666426
18.

DNA vaccination: using the patient's immune system to overcome cancer.

Eschenburg G, Stermann A, Preissner R, Meyer HA, Lode HN.

Clin Dev Immunol. 2010;2010:169484. doi: 10.1155/2010/169484. Review.

19.

[Anti-HER2 vaccines: The HER2 immunotargeting future?].

Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I.

Pathol Biol (Paris). 2011 Jun;59(3):173-82. doi: 10.1016/j.patbio.2009.04.002. Review. French.

PMID:
19481373
20.

Part I: Vaccines for solid tumours.

Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D.

Lancet Oncol. 2004 Nov;5(11):681-9. Review. Erratum in: Lancet Oncol. 2005 Jan;6(1):4.

PMID:
15522656
Items per page

Supplemental Content

Support Center